The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge

Drug Safety

Volumn 29, Issue 1, 2006, Pages 79-90

  Straubhaar, Bernhard ^a   Krähenbühl, Stephan ^a,b   Schlienger, Raymond G ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; AMOXICILLIN; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAXATIVE; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; MINERAL; PHENPROCOUMON; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; PROTON PUMP INHIBITOR; RESPIRATORY TRACT AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG; VASODILATOR AGENT;

AGED; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BRADYCARDIA; CARDIOTOXICITY; CLINICAL TRIAL; COMPUTER PROGRAM; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NUTRITIONAL DISORDER; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SAMPLE SIZE; STATISTICAL SIGNIFICANCE;

AGED; CARDIOVASCULAR AGENTS; COMORBIDITY; DRUG INTERACTIONS; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; POLYPHARMACY; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 32244438355     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629010-00006     Document Type: Article

References (44)

1. Masoudi FA, Krumholz HM. Polypharmacy and comorbidity in heart failure. BMJ 2003; 327 (7414): 513-4
2. Ledwidge M, Travers B, Ryder M, et al. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail 2004; 6 (2): 235-43
3. Martinez-Selles M, Garcia Robles JA, Munoz R, et al. Pharmacological treatment in patients with heart failure: patients knowledge and occurrence of polypharmacy, alternative medicine and immunizations. Eur J Heart Fail 2004; 6 (2): 219-26
4. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12 (6): 485-94
5. Köhler GI, Bode-Boger SM, Busse R, et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38 (11): 504-13
6. Ratz Bravo A, Tchambaz L, Krähenb̈uhl-Melcher A, et al. The prevalence of potentially critical drug-drug interactions in ambulatory dyslipidemic patients treated with statins. Drug Saf 2005; 28 (3): 263-75
7. Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003; 21 (3): 153-8
8. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58 (11): 773-8
9. Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet 2003; 362 (9378): 147-58
10. Rosholm JU, Bjerrum L, Hallas J, et al. Polypharmacy and the risk of drug-drug interactions among Danish elderly: a prescription database study. Dan Med Bull 1998; 45 (2): 210-3
11. Bergk V, Gasse C, Rothenbacher D, et al. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76 (1): 85-96
12. Bergendal L, Friberg A, Schaffrath A. Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 1995; 17 (5): 152-7
13. Björkman IK, Fastbom J, Schmidt IK, et al. Drug-drug interactions in the elderly. Ann Pharmacother 2002; 36 (11): 1675-81
14. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9 (1): 51-9
15. Di Castri A, Jacquot JM, Hemmi P, et al. Intéractions ḿedicamenteuses: etudes de 409 ordonnances établies à l'issue d'une hospitalisation ǵeriatrique. Therapie 1995; 50 (3): 259-64
16. Dettli L. Drug dosage in patients with renal disease. Clin Pharmacol Ther 1974; 16 (1): 274-80
17. Klasco RK, Moore LE. Drug-Reax® System. Greenwood Village (CO): MICROMEDEX, 2004
18. Gaddis GM, Holt TR, Woods M. Drug interactions in at-risk emergency department patients. Acad Emerg Med 2002; 9 (11): 1162-7
19. Langdorf MI, Fox JC, Marwah RS, et al. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 2000; 7 (11): 1321-9
20. Meredith PA. Is postural hypotension a real problem with antihypertensive medication? Cardiology 2001; 96 Suppl. 1: 19-24
21. Mignat C, Unger T. ACE inhibitors: drug interactions of clinical significance. Drug Saf 1995; 12 (5): 334-47
22. Tan LB, Williams SG, Goldspink DF. From CONSENSUS to CHARM: how do ACEI and ARB produce clinical benefits in CHF? Int J Cardiol 2004; 94 (2-3): 137-41
23. Klein L, O'Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003; 91 (9A): 18F-40F
24. Bouvy ML, Heerdink ER, Leufkens HG, et al. Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. Eur J Heart Fail 2003; 5 (2): 195-200
25. Ageno W, Turpie AG. Low molecular weight heparins in the treatment of unstable angina. Minerva Cardioangiol 2002; 50 (6): 643-51
26. Shullo MA, Rose ML, Vivas C, et al. Hemorrhagic complications of enoxaparin and aspirin in patients with kidney transplants. Pharmacotherapy 2002; 22 (2): 184-7
27. Farooq V, Hegarty J, Chandrasekar T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004; 43 (3): 531-7
28. Haustein KO. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon. Semin Thromb Hemost 1999; 25 (1): 5-11
29. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000; 109 (4): 307-14
30. McAlister FA, Ezekowitz J, Tonelli M, et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109 (8): 1004-9
31. Schepkens H, Vanholder R, Billiouw JM, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110 (6): 438-41
32. Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004; 10 (4): 297-303
33. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med 1998; 158 (1): 26-32
34. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 709-17
35. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351 (6): 543-51
36. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10 (4): 499-509
37. Leor J, Levartowsky D, Sharon C, et al. Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol. Am Heart J 1988; 116 (1 Pt 1): 206-7
38. Yamreudeewong W, DeBisschop M, Martin L, et al. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003; 26 (6): 421-38
39. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99 (17): 2268-75
40. Krum H, Shusterman N, MacMahon S, et al. Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group. J Card Fail 1998; 4 (4): 281-8
41. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001; 15 (6): 897-918
42. Juurlink DN, Mamdani MM, Kopp A, et al. A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin. Br J Clin Pharmacol 2005; 59 (1): 102-7
43. Chen YF, Avery AJ, Neil KE, et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005; 28 (1): 67-80
44. Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003; 20 (10): 769-76